A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis.
Osama MosalemWinston TanAlan H BryceRoxana S DroncaDaniel S ChildsLance C PagliaroJacob J OrmeAdam M KasePublished in: Prostate cancer and prostatic diseases (2024)
Our hypothesis-generating study suggests that MSI-H drives the efficacy of pembrolizumab in mCRPC with better survival outcomes as TMB increases. Clinicians should consider alternative treatment strategies for advanced prostate cancer when TMB-H is present without co-occurring MSI-H or CDK12.